{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:32:51Z","timestamp":1791073971802,"version":"4.1.0"},"reference-count":70,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review was conducted to systematically identify evidence characterizing patients with migraine who are unsuitable for triptans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triptans are not suitable as first\u2010line treatment for all patients with migraine due to contraindications, lack of efficacy, and\/or poor tolerability. However, there is debate about the frequency and characteristics of these patients and the burden they experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, Embase, and conference abstracts (2011\u20132022) were reviewed for evidence on patients with migraine unsuitable for triptans for any reason. Data from publications describing the frequency and characteristics of this group, as well as the clinical, humanistic, or economic burden of disease in this population, were extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1460 records screened, 29 publications met inclusion criteria. Persistence with triptans was low; 51%\u201366% of patients starting a new triptan did not refill it, and 43%\u2013100% discontinued their initial triptan over 2\u2009years. In one study, 14% of patients with migraine reported prior discontinuation\/failure of \u2265\u20092 triptans due to inadequate efficacy or poor tolerability. Up to 15% of patients with migraine had triptan contraindications, and \u2265\u200920% of patients receiving triptans had contraindications. In four studies, 10%\u201344% of patients who tried triptans had insufficient response, although definitions varied. Patients who achieved a sufficient response typically did so with their first triptan; few became responders with additional triptans. Of patients who did not respond to one to two triptans and received another, 45% were dissatisfied with the final triptan. Approximately half of patients who tried two to three triptans had an insufficient response. Greater disability, impact of disease, and depression were reported in triptan discontinuers compared to those with sustained use. Worse quality of life scores and utility values were reported in triptan insufficient versus sufficient responders, as were greater migraine\u2010related costs, work impairment, and health\u2010care resource utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The total population of patients unsuitable for triptans is uncertain, but the literature highlights a large group who cannot or do not persist with triptans, and current evidence suggests a high burden in this population and an unmet need for new therapeutic options. Further research is needed to determine the frequency of unsuitability for triptans more precisely and to assess the associated burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14854","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T04:35:23Z","timestamp":1732682123000},"page":"164-179","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A\u00a0systematic literature review"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[{"name":"Albert Einstein College of Medicine  Bronx New York USA"},{"name":"Montefiore Medical Center  Bronx New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[{"name":"Private Practice  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-8621","authenticated-orcid":false,"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd.  Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-9388","authenticated-orcid":false,"given":"Aaron","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd.  Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jersen","family":"Telfort","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-7099","authenticated-orcid":false,"given":"Karin Hygge","family":"Blakeman","sequence":"additional","affiliation":[{"name":"Pfizer AB  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Saccone","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5012-6686","authenticated-orcid":false,"given":"Iwona","family":"Pustulka","sequence":"additional","affiliation":[{"name":"Evidera  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6530-1111","authenticated-orcid":false,"given":"Iain","family":"Fotheringham","sequence":"additional","affiliation":[{"name":"Evidera Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1927-0401","authenticated-orcid":false,"given":"Anita","family":"Engh","sequence":"additional","affiliation":[{"name":"Evidera  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"issue":"4","key":"e_1_2_12_3_1","first-page":"243","article-title":"Acute migraine headache: treatment strategies","volume":"97","author":"Mayans L","year":"2018","journal-title":"Am Fam Physician"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002275"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2"},{"key":"e_1_2_12_8_1","volume-title":"Facts About Migraine","author":"American Migraine Foundation","year":"2023"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02223.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5"},{"issue":"1","key":"e_1_2_12_12_1","first-page":"S3","article-title":"European principles of management of common headache disorders in primary care","volume":"8","author":"Steiner TJ","year":"2007","journal-title":"J Headache Pain"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.07.006"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2514183X18823377"},{"key":"e_1_2_12_15_1","volume-title":"Commonly Used Acute Migraine Treatments","author":"American Migraine Foundation","year":"2019"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"issue":"2","key":"e_1_2_12_17_1","first-page":"S23","article-title":"Migraine overview and summary of current and emerging treatment options","volume":"25","author":"Peters GL","year":"2019","journal-title":"Am J Manag Care"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13179"},{"issue":"1","key":"e_1_2_12_19_1","first-page":"S1","article-title":"Treatment patterns and unmet needs in the acute treatment of migraine","volume":"69","author":"Lipton RB","year":"2020","journal-title":"J Fam Pract"},{"key":"e_1_2_12_20_1","article-title":"Triptans for acute cluster headache","volume":"7","author":"Derry S","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.11.025"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01494-9"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80008-4"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905307"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02451-x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.7.1011"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01502-z"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941839"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1060-6"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989247"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171171228-42"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1076-6"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12962"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-48"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/2150132720963680"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12820"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00304-w"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00223-y"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01848-4"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01790.x"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.12.020"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01378-5"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410383058"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00167-3"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12154"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01110-9"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420915167"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-47"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1842733"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.5054"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412449929"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410390399"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413497599"},{"issue":"2","key":"e_1_2_12_56_1","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221143773","article-title":"Place of next generation acute migraine specific treatments among triptans, non\u2010responders and contraindications to triptans and possible combination therapies","volume":"43","author":"Boer I","year":"2023","journal-title":"Cephalalgia"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01676-0"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413499649"},{"key":"e_1_2_12_59_1","unstructured":"GlaxoSmithKline.Imitrex (Sumatriptan Succinate) US Prescribing Information.2021."},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415593086"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-022-03299-6"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-021-00371-8"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721110-00001"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646946"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00404.x"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"issue":"1","key":"e_1_2_12_68_1","first-page":"392","article-title":"A descriptive analysis of the burden of migraine based on self\u2010reported migraine diary data using the migraine buddy application in Europe","volume":"24","author":"Paris N","year":"2017","journal-title":"Eur J Neurol"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13716"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00331-3"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01185-4"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:41:25Z","timestamp":1762083685000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/head.14854"],"URL":"https:\/\/doi.org\/10.1111\/head.14854","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"2024-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}